| Literature DB >> 35992024 |
Liang Mo1, Jianxiong Li1, Zhangzheng Wang1, Fayi Huang1, Pengfei Xin1, Chi Zhou1, Wei He1, Yuhao Liu1.
Abstract
The purpose of this study was to evaluate the outcomes of total hip arthroplasty (THA) following less invasive hip-preserving procedures (LIHPs) and present a critical overview of the literature to aid in better result interpretation. The search time was from the establishment of the database to September 2021, and the outcome indicators were extracted and analyzed by Cochrane Collaboration Review Manager software (RevMan version 5.4). Finally, 10 articles were included in this meta-analysis by searching Chinese databases and English databases. Three of them were published in Chinese, and the remaining studies were published in English. LIHP was further divided into the tantalum rod implantation group and the non-tantalum rod implantation group. The results showed that prior tantalum rod implantation increased the difficulty of conversion to THA, which was reflected mainly in the longer operative time [weighted mean difference (WMD) = 24.50, 95% confidence interval (CI) = 14.09-34.91, P < 0.00001] and greater intraoperative blood loss (WMD = 114.74, 95% CI = 33.52-195.96, P = 0.006), while no significant difference was found between the non-tantalum rod implantation group and the control group. Simultaneously, easier intraoperative fracture [odds ratio (OR) = 5.88, 95% CI = 0.93-37.05, P = 0.06] and stem malalignment (OR = 4.17, 95% CI = 1.18-14.71, P = 0.03) in the LIHP group tended to be observed than in the control THA group. However, there was no significant difference in cup anteversion and inclination angle, ectopic ossification, postoperative Harris Hip Score and survivorship between the LIHP group and the control group. Although LIHP increased the difficulty of the conversion to THA, it does not detrimentally affect the clinical results of subsequent THA in the mid-term follow-up.Entities:
Year: 2022 PMID: 35992024 PMCID: PMC9389913 DOI: 10.1093/jhps/hnac035
Source DB: PubMed Journal: J Hip Preserv Surg ISSN: 2054-8397
Fig. 1.Flowchart of the literature search and study inclusion.
NOS and basic information of the included studies
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| Lim SJ [ | 2008 | 1995–2004 | Korea | RCS | *** | ** | *** | 8 |
| Issa K [ | 2014 | 2001–2010 | American | RCS | *** | ** | *** | 8 |
| Lee GW [ | 2016 | 2010–2011 | Korea | RCS | *** | ** | *** | 8 |
| Olsen [ | 2016 | 2002–2013 | Canada | RCS | *** | ** | *** | 8 |
| Cheng Q [ | 2018 | 2007–2012 | China | RCS | *** | ** | *** | 8 |
| Chu YM [ | 2018 | 2013–2015 | China | RCC | ** | ** | *** | 7 |
| Cai J [ | 2018 | 2010–2012 | China | RCC | ** | ** | *** | 7 |
| Ma J [ | 2019 | 2009–2014 | China | RCC | *** | ** | *** | 8 |
| Zuo W [ | 2020 | 2010–2014 | China | RCC | *** | ** | *** | 8 |
| Chu YM [ | 2020 | 2013–2017 | China | RCS | *** | ** | *** | 8 |
RCC: retrospective case–control study; RCS: retrospective cohort study; * represents one score point.
Summary results of meta-analysis
|
| |||||
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| Operative time | Non-tantalum | 3 [ | 3.15 [−3.46, 9.75] | 0.35 | 71 |
| Tantalum | 5 [ | 24.50 [14.09, 34.91] | <0.00001 | 90 | |
| Total | 8 | 16.32 [6.72, 25.93] | 0.0009 | 95 | |
| Intraoperative blood loss | Non-tantalum | 3 [ | 0.82 [−28.32, 29.96] | 0.96 | 0 |
| Tantalum | 4 [ | 114.74 [33.52, 195.96] | 0.006 | 93 | |
| Total | 7 | 68.96 [11.90, 126.02] | 0.02 | 91 | |
| Intraoperative fracture | Non-tantalum | 2 [ | 5.62 [0.62, 50.89] | 0.12 | 0 |
| Tantalum | 1 [ | 6.60 [0.24, 181.64] | 0.26 | 0 | |
| Total | 3 | 5.88 [0.93, 37.05] | 0.06 | 0 | |
| Ectopic ossification | Non-tantalum | 2 [ | 2.24 [0.48, 10.51] | 0.31 | 0 |
| Stem malalignment | Non-tantalum | 2 [ | 5.51 [1.24, 24.45] | 0.02 | 0 |
| Tantalum | 1 [ | 1.95 [0.17, 22.37] | 0.59 | ∼ | |
| Total | 3 | 4.17 [1.18, 14.71] | 0.03 | 0 | |
| Cup anteversion angle | Non-tantalum | 1 [ | 0.36 [−0.67, 1.39] | 0.50 | ∼ |
| Tantalum | 5 [ | −0.25 [−0.84, 0.34] | 0.40 | 0 | |
| Total | 6 | −0.10 [−0.64, 0.41] | 0.70 | 0 | |
| Cup inclination angle | Non-tantalum | 3 [ | 0.36 [−0.57, 1.29] | 0.45 | 0 |
| Tantalum | 5 [ | 0.62 [−0.13, 1.37] | 0.11 | 0 | |
| Total | 8 | 0.52 [−0.07, 1.10] | 0.08 | 0 | |
| Postoperative HHS | Non-tantalum | 5 [ | 0.44 [−0.22, 1.10] | 0.19 | 7 |
| Tantalum | 5 [ | −0.07 [−0.59, 0.45] | 0.78 | 59 | |
| Total | 10 | 0.12 [−0.29, 0.53] | 0.56 | 42 | |
| Survivorship | Non-tantalum | 2 [ | 1.72 [0.37, 7.92] | 0.49 | 0 |
| Tantalum | 1 [ | 0.32 [0.01, 8.24] | 0.49 | ∼ | |
| Total | 3 | 1.18 [0.31, 4.54] | 0.81 | 0 | |
Fig. 2.(A) Funnel plot for operative blood loss. (B) Funnel plot for operative time. An asymmetry was exhibited in the funnel plot, which reflected the publication bias.
Basic characteristics of the included studies
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Lim SJ [ | CD cement | 23 | 16/7 | NR | 40 ± 10 | 55 ± 33 | 43(4–137) |
| Control | 39 | 23/9 | NR | 43 ± 10 | 57 ± 34 | – | |
| Issa K ① [ | CD | 19 | NR | 30 (17–45) | 45 (18–74) | 67 (32–107) | 20(6–56) |
| Issa K ② [ | Bone grafting | 29 | NR | 25 (18–44) | 38 (18–81) | 75 (13–122) | 27(5–122) |
| Control | 121 | NR | 26 (15–42) | 41 (12–71) | 77 (38–124) | – | |
| Lee GW [ | Tantalum rod | 8 | 6/0 | 23.7 (20.5–25.6) | 36.3 (32–39) | 39.8 (36–57) | NR |
| Control | 16 | 12/0 | 22.8 (18.8–27.7) | 36.6 (32–39) | 42.6 (38–57) | – | |
| Olsen [ | Tantalum rod | 21 | 12/9 | NR | 37(18–53) | 50.4(24–72) | 26(6–72) |
| Control | 21 | 12/9 | NR | 40(18–58) | NR | – | |
| Cheng Q [ | Tantalum rod | 39 | 26/5 | 25.2 (22.3–26.4) | 49.3(36–64) | 88.8(60–120) | 33.1(16–63) |
| Control | 40 | 26/7 | 24.6 (21.5–25.6) | 43.2 (37–64) | 88.8(60–120) | – | |
| Chu YM [ | Bone grafting | 27 | 19/8 | 27.9 ± 4.5 | 43.7 ± 14.7 | 46.4 ± 9.6 | 63.6 |
| Control | 42 | 31/11 | 26.4 ± 3.7 | 45.9 ± 13.3 | 49.8 ± 9.2 | – | |
| Cai J [ | Bone grafting | 34 | 20/11 | NR | 52(42–65) | 29.3 | 58.8 |
| Control | 41 | 23/12 | NR | 50.5(34–64) | 28.4 | ||
| Ma J [ | Tantalum rod | 34 | 21/11 | 24.9 ± 4.2 | 43.6 ± 7.6 | 64.1 ± 14.7 | 64.1 ± 14.7 |
| Control | 32 | 16/9 | 25.3 ± 4.2 | 44.0± 10.7 | 59.4 ± 9.7 | – | |
| Zuo W ① [ | Tantalum rod | 30 | NR | 24.05 (17.6–31.2) | 41(21–60) | 64 (52–88) | 31(5–66) |
| Zuo W ② [ | Bone grafting | 30 | NR | 23.59 (18.6–30.2) | 42 (26–65) | 59 (49–91) | 39(3–77) |
| Control | 30 | NR | 25.45 (17.9–37.5) | 41 (23–63) | 62 (54–85) | – | |
| Chu YM [ | Tantalum rod | 44 | 29/15 | 25.92 ± 3.42 | 43.7 ± 14.7 | 37.91 ± 7.18 | NR |
| Control | 42 | 31/11 | 25.24 ± 3.68 | 45.9 ± 13.3 | 37.91 ± 7.18 | – |
M: male; F: female; NR: not reported; ① and ②: different subgroups from a study.